February 2, 2024 11:08 AM EST
News Briefing

Hutchmed's li­cens­ing deal, worth up to $227M; Tyra's $200 PIPE

Jaimy Lee

Deputy Editor

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics:

Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times